Indapamide-CRCa, 1.5 mg 30 pcs

Thiazide-like diuretic, antihypertensive agent. Causes reduction of arterial smooth muscle tone, decreases PPS, also has moderate saluretic activity due to disruption of reabsorption of sodium, chlorine and water ions in the cortical segment of the Genle loop and proximal convoluted tubule of nephron.

The reduction of RPS is due to several mechanisms: decreased sensitivity of the vascular wall to noradrenaline and angiotensin II; increased synthesis of prostaglandins with vasodilatory activity; inhibition of calcium ion influx into the smooth muscle elements of the vascular wall. In therapeutic doses has almost no effect on lipid and carbohydrate metabolism.

Hypotensive effect appears only at initially elevated BP, develops by the end of the first week and reaches a maximum after 3 months of systematic use.

Indications

Arterial hypertension; sodium and water retention in chronic heart failure.

Pharmacological effect

Thiazide-like diuretic, antihypertensive agent. Causes a decrease in the tone of the smooth muscles of the arteries, a decrease in peripheral vascular resistance, and also has moderate saluretic activity due to impaired reabsorption of sodium, chlorine and water ions in the cortical segment of the loop of Henle and the proximal convoluted tubule of the nephron.

The decrease in peripheral vascular resistance is due to several mechanisms: a decrease in the sensitivity of the vascular wall to norepinephrine and angiotensin II; increased synthesis of prostaglandins with vasodilating activity; inhibition of the influx of calcium ions into the smooth muscle elements of the vascular wall. In therapeutic doses, it has virtually no effect on lipid and carbohydrate metabolism.

The hypotensive effect appears only when blood pressure is initially elevated, develops by the end of the first week and reaches a maximum after 3 months of systematic use.

Special instructions

Use with caution in patients with diabetes mellitus (glucose levels need to be controlled, especially in the presence of hypokalemia), gout (an increase in the number of attacks is possible), and in patients with a history of allergic reactions to sulfonamide derivatives.

During treatment, it is necessary to monitor the level of electrolytes in the blood plasma (potassium, sodium, calcium).

Active ingredient

Indapamide

Composition

1 tab. contains indapamide 1.5 mg

Contraindications

Acute cerebrovascular accident, severe renal and/or liver dysfunction, severe forms of diabetes mellitus and gout, hypersensitivity to indapamide.

Side Effects

From the digestive system: nausea, discomfort or pain in the epigastrium.

From the side of the central nervous system: weakness, fatigue, dizziness, nervousness.

From the cardiovascular system: orthostatic hypotension.

Metabolism: hypokalemia, hyperuricemia, hyperglycemia, hyponatremia, hypochloremia.

Allergic reactions: skin manifestations.

Interaction

With the simultaneous use of GCS and tetracosactide for systemic use, the hypotensive effect is reduced due to the retention of water and sodium ions under the influence of GCS.

When used simultaneously with ACE inhibitors, the risk of developing hyponatremia increases.

When used simultaneously with NSAIDs (for systemic use), the hypotensive effect of indapamide may be reduced. With significant fluid loss, acute renal failure may develop (due to a sharp decrease in glomerular filtration).

When used simultaneously with calcium supplements, hypercalcemia may develop due to decreased excretion of calcium ions in the urine.

When used simultaneously with cardiac glycosides and corticosteroids, the risk of developing hypokalemia increases.

With the simultaneous use of drugs that can cause hypokalemia (amphotericin B, gluco- and mineralocorticoids, tetracosactide, laxatives that stimulate intestinal motility), the risk of developing hypokalemia increases.

When used simultaneously with tricyclic antidepressants (including imipramine), the hypotensive effect is enhanced and the risk of developing orthostatic hypotension increases (additive effect).

When used simultaneously with astemizole, bepridil, erythromycin (iv), pentamidine, sultopride, terfenadine, vincamine, quinidine, disopyramide, amiodarone, bretylium tosylate, sotalol, there is a risk of developing pirouette-type arrhythmia.

When used simultaneously with baclofen, the hypotensive effect is enhanced.

When used simultaneously with halofantrine, the likelihood of cardiac arrhythmia (including ventricular arrhythmia of the “pirouette” type) increases.

When used simultaneously with lithium carbonate, the risk of developing the toxic effect of lithium increases due to a decrease in its renal clearance.

When used simultaneously with metformin, lactic acidosis may occur, which is apparently associated with the development of functional renal failure caused by the action of diuretics (mainly loop diuretics).

When used simultaneously with cyclosporine, an increase in the creatinine content in the blood plasma is possible, which is observed even with normal levels of water and sodium ions.

Manufacturer

KRKA-RUS, Russia